1
|
Corsini CA, Martins PFDS, Filgueiras PS, Lourenço AJ, Lima AEDS, Gomes SVC, Jeremias WDJ, Alves PA, Fernandes GDR, Castro LLME, de Carvalho AT, Azevedo ACC, Curimbaba CDAL, Lorencini DA, Junior EM, da Silva VM, Cervi MC, Borges MDC, Nogueira ML, Campos GRF, Correa PRL, Carvalho TML, dos Reis JGAC, Reis EVDS, Castilho LDR, de Lima PR, do Nascimento JPR, de Oliveira JG, Filho OAM, Grenfell RFQE. Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up. Res Sq 2024:rs.3.rs-3931021. [PMID: 38464059 PMCID: PMC10925469 DOI: 10.21203/rs.3.rs-3931021/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
Introduction Vaccines are essential for the prevention and control of several diseases, indeed, monitoring the immune response generated by vaccines is crucial. The immune response generated by vaccination against SARS-CoV-2 in children and adolescents is not well defined regarding to the intensity and medium to long-term duration of a protective immune response, which may point out the need of booster doses and might support the decisions in public health. Objective The study aims to evaluate the immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in a two-dose primary protocol in children and adolescent aging from 3 to 17 years old in Brazil. Methods Participants were invited to participate in the research at two public healthcare centers located in Serrana (São Paulo) and Belo Horizonte (Minas Gerais), Brazil. Participants underwent medical interviews to gather their medical history, including COVID-19 history and medical records. Physical exams were conducted, including weight, blood pressure, temperature, and pulse rate measurements. Blood samples were obtained from the participants before vaccination, 1 month after the first dose, and 1, 3, and 6 months after the second dose and were followed by a virtual platform for monitoring post-vaccination reactions and symptoms of COVID-19. SARS-CoV-2 genome from Swab samples of COVID-19 positive individuals were sequenced by NGS. Total antibodies were measured by ELISA and neutralizing antibodies to B.1 lineage and Omicron variant (BA.1) quantified by PRNT and VNT. The cellular immune response was evaluated by flow cytometry by the quantification of systemic soluble immune mediators. Results The follow-up of 640 participants showed that the CoronaVac vaccine (Sinovac/Butantan Institute) was able to significantly induce the production of total IgG antibodies to SARS-CoV-2 and the production of neutralizing antibodies to B.1 lineage and Omicron variant. In addition, a robust cellular immune response was observed with wide release of pro-inflammatory and regulatory mediators in the early post-immunization moments. Adverse events recorded so far have been mild and transient except for seven serious adverse events reported on VigiMed. Conclusions The results indicate a robust and sustained immune response induced by the CoronaVac vaccine in children and adolescents up to six months, providing evidences to support the safety and immunogenicity of this effective immunizer.
Collapse
Affiliation(s)
- Camila Amormino Corsini
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | | | - Priscilla Soares Filgueiras
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Adelina Júnia Lourenço
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Ana Esther de Souza Lima
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Sarah Vieira Contin Gomes
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Wander de Jesus Jeremias
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
- Department of Pharmacy, Federal University of Ouro Preto (UFOP). 27, Nove, Bauxita, Ouro Preto, Brazil. 35400-000
| | - Pedro Augusto Alves
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Gabriel da Rocha Fernandes
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | | | - Andrea Teixeira de Carvalho
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Ana Carolina Campi Azevedo
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | | | | | | | | | - Maria Célia Cervi
- Faculty of Medicine, University of São Paulo (USP). 455 Doutor Arnaldo Avenue, São Paulo, São Paulo, Brazil. 01246-903
| | - Marcos de Carvalho Borges
- Faculty of Medicine, University of São Paulo (USP). 455 Doutor Arnaldo Avenue, São Paulo, São Paulo, Brazil. 01246-903
- Serrana Clinical Research Center. 438, 13 de Maio, Centro, Serrana, São Paulo, Brazil. 14150-000
| | - Maurício Lacerda Nogueira
- Faculty of Medicine of São José do Rio Preto (FAMERP). 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, São Paulo, Brazil. 15090-000
- Hospital de Base, 5544 Brigadeiro Faria Lima Avenue, São José do Rio Preto, São Paulo State, Brazil. 15090-000
- Department of Pathology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, USA. 77555
| | | | - Paulo Roberto Lopes Correa
- Belo Horizonte Municipal Health Department (SMS), 2336 Afonso Pena Avenue, Belo Horizonte, Brazil. 30130-012
| | | | | | - Erik Vinícius de Sousa Reis
- Federal University of Minas Gerais (UFMG). 6627 Presidente Antônio Carlos Avenue, Belo Horizonte, Minas Gerais, Brazil. 31270-901
| | - Leda dos Reis Castilho
- Cell Culture Engineering Laboratory (COPPE), Federal University of Rio de Janeiro (UFRJ). 550 Pedro Calmon Avenue, Rio de Janeiro, Rio de Janeiro, Brazil. 21941-598
| | | | | | | | - Olindo Assis Martins Filho
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Rafaella Fortini Queiroz e Grenfell
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
- Federal University of Minas Gerais (UFMG). 6627 Presidente Antônio Carlos Avenue, Belo Horizonte, Minas Gerais, Brazil. 31270-901
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia (UGA). 501 DW Brooks Drive, Athens, Georgia, USA. 30602-7387
| | | |
Collapse
|
2
|
Filgueiras PS, Corsini CA, Almeida NBF, Pedrosa MLC, Miranda DAPD, Gomes SVC, Assis JVD, Silva RA, Medeiros MIVDARCD, Lourenço AJ, Bicalho CMF, Vilela RVR, Jeremias WDJ, Fernandes GDR, Queiroz RFGE. Rapid antigen test as a tool for the identification of SARS-CoV-2 infection and its potential as a self-testing device. Rev Soc Bras Med Trop 2023; 56:e01672022. [PMID: 37222349 DOI: 10.1590/0037-8682-0167-2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Accepted: 03/01/2023] [Indexed: 05/25/2023] Open
Abstract
BACKGROUND SARS-CoV-2 virus originated in Wuhan (China) in December (2019) and quickly spread worldwide. Antigen tests are rapid diagnostic tests (RDT) that produce results in 15-30 min and are an important tool for the scale-up of COVID-19 testing. COVID-19 diagnostic tests are authorized for self-testing at home in some countries, including Brazil. Widespread COVID-19 diagnostic testing is required to guide public health policies and control the speed of transmission and economic recovery. METHODS Patients with suspected COVID-19 were recruited at the Hospital da Baleia (Belo Horizonte, Brazil). The SARS-CoV-2 antigen-detecting rapid diagnostic tests were evaluated from June 2020 to June 2021 using saliva, nasal, and nasopharyngeal swab samples from 609 patients. Patient samples were simultaneously tested using a molecular assay (RT-qPCR). Sensitivity, specificity, accuracy, and positive and negative predictive values were determined using the statistical program, MedCalc, and GraphPad Prism 8.0. RESULTS The antigen-detecting rapid diagnostic tests displayed 98% specificity, 60% sensitivity, 96% positive predictive value, and moderate concordance with RT-qPCR. Substantial agreement was found between the two methods for patients tested < 7 days of symptom onset. CONCLUSIONS Our findings support the use of Ag-RDT as a valuable and safe diagnostic method. Ag-RDT was also demonstrated to be an important triage tool for suspected COVID-19 patients in emergencies. Overall, Ag-RDT is an effective strategy for reducing the spread of SARS-CoV-2 and contributing to COVID-19 control.
Collapse
Affiliation(s)
- Priscilla Soares Filgueiras
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
- Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Programa de Pós-Graduação em Patologia, Belo Horizonte, MG, Brasil
| | - Camila Amormino Corsini
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
| | - Nathalie Bonatti Franco Almeida
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
- Universidade da Geórgia, Faculdade de Medicina Veterinária, Departamento de Doenças Infecciosas, Athens, GA, Estados Unidos da América
| | - Maria Luysa Camargos Pedrosa
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
| | - Daniel Alvim Pena de Miranda
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
| | - Sarah Vieira Contin Gomes
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
| | - Jéssica Vieira de Assis
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
- Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Programa de Pós-Graduação em Patologia, Belo Horizonte, MG, Brasil
| | | | | | | | | | | | - Wander de Jesus Jeremias
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
- Universidade Federal de Ouro Preto, Departamento de Farmácia, Ouro Preto, MG, Brasil
| | | | - Rafaella Fortini Grenfell E Queiroz
- Fundação Oswaldo Cruz, Instituto René Rachou, Diagnóstico e Terapia de Doenças Infecciosas e Câncer, Belo Horizonte, MG, Brasil
- Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Programa de Pós-Graduação em Patologia, Belo Horizonte, MG, Brasil
- Universidade da Geórgia, Faculdade de Medicina Veterinária, Departamento de Doenças Infecciosas, Athens, GA, Estados Unidos da América
| |
Collapse
|
3
|
Almeida NBF, Filgueiras PS, Lourenço AJ, Bicalho CMF, Corsini CA, de Miranda DAP, Gomes SVC, Vilela RVR, Grenfell RFQ. COVID-19 in patients with chronic kidney disease: a 2-year study of incidence and mortality in relation to the variants of concern waves in Brazil. Trans R Soc Trop Med Hyg 2023:7115601. [PMID: 37042271 DOI: 10.1093/trstmh/trad019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 02/15/2023] [Accepted: 03/26/2023] [Indexed: 04/13/2023] Open
Abstract
BACKGROUND Chronic kidney disease (CKD) is a risk factor for severe coronavirus disease (COVID-19). In Brazil, the disease is the 10th highest cause of death. We evaluated the epidemiological impact of COVID-19 in CDK and non-CDK patients. METHODS Positive patients for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from 2020 to 2022 were classified according to the severity of COVID-19 and the numbers of cases and deaths were correlated to each wave of SARS-CoV-2 variants in Brazil. RESULTS We compared all variables, and our data show that CDK significantly increased the mortality rate among patients, especially before COVID-19 vaccination, in comparison with non-CKD patients. CONCLUSIONS CKD patients had a significantly increased mortality rate compared with non-CKD.
Collapse
Affiliation(s)
- Nathalie Bonatti Franco Almeida
- Diagnosis and Therapy of Infectious Diseases and Cancer, Rene Rachou Institute, Oswaldo Cruz Foundation (FIOCRUZ), 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, 30190-002, Brazil
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, 501 DW Brooks Drive, Athens, Georgia, 30602-7387, USA
| | - Priscilla Soares Filgueiras
- Diagnosis and Therapy of Infectious Diseases and Cancer, Rene Rachou Institute, Oswaldo Cruz Foundation (FIOCRUZ), 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, 30190-002, Brazil
- Institute of Biological Sciences, Federal University of Minas Gerais, 6627 Presidente Antônio Carlos Avenue, Belo Horizonte, Minas Gerais, 31270-901, Brazil
| | - Adelina Junia Lourenço
- Hospital da Baleia, Benjamin Guimarães Foundation, 1464 Juramento, Belo Horizonte, Minas Gerais, 30285-408, Brazil
| | | | - Camila Amormino Corsini
- Diagnosis and Therapy of Infectious Diseases and Cancer, Rene Rachou Institute, Oswaldo Cruz Foundation (FIOCRUZ), 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, 30190-002, Brazil
| | - Daniel Alvim Pena de Miranda
- Diagnosis and Therapy of Infectious Diseases and Cancer, Rene Rachou Institute, Oswaldo Cruz Foundation (FIOCRUZ), 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, 30190-002, Brazil
| | - Sarah Vieira Contin Gomes
- Diagnosis and Therapy of Infectious Diseases and Cancer, Rene Rachou Institute, Oswaldo Cruz Foundation (FIOCRUZ), 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, 30190-002, Brazil
| | - Raquel V R Vilela
- Hospital da Baleia, Benjamin Guimarães Foundation, 1464 Juramento, Belo Horizonte, Minas Gerais, 30285-408, Brazil
| | - Rafaella Fortini Queiroz Grenfell
- Diagnosis and Therapy of Infectious Diseases and Cancer, Rene Rachou Institute, Oswaldo Cruz Foundation (FIOCRUZ), 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, 30190-002, Brazil
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, 501 DW Brooks Drive, Athens, Georgia, 30602-7387, USA
- Institute of Biological Sciences, Federal University of Minas Gerais, 6627 Presidente Antônio Carlos Avenue, Belo Horizonte, Minas Gerais, 31270-901, Brazil
| |
Collapse
|
4
|
Campos GRF, Almeida NBF, Filgueiras PS, Corsini CA, Gomes SVC, de Miranda DAP, de Assis JV, de Souza Silva TB, Alves PA, da Rocha Fernandes G, de Oliveira JG, Rahal P, Grenfell RFQ, Nogueira ML. Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant. Commun Med (Lond) 2022; 2:76. [PMID: 35784447 PMCID: PMC9242982 DOI: 10.1038/s43856-022-00141-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 06/14/2022] [Indexed: 01/07/2023] Open
Abstract
Background The emergence of the new SARS-CoV-2 Omicron variant, which is known to have a large number of mutations when compared to other variants, brought to light the concern about vaccine escape, especially from the neutralization by antibodies induced by vaccination. Methods Based on viral microneutralization assays, we evaluated in 90 individuals the impact on antibody neutralization induction, against Omicron variant, by a booster dose of BNT162b2 mRNA vaccine after the CoronaVac primary vaccination scheme. Results Here we show that the percentage of seroconverted individuals 30 and 60 days after CoronaVac scheme was 16.6% and 10%, respectively. After booster dose administration, the seroconvertion rate increased to 76.6%. The neutralization mean titer against Omicron in the CoronaVac protocol decreased over time, but after the booster dose, the mean titer increased 43.1 times. Conclusions These results indicate a positive impact of this vaccine combination in the serological immune response against SARS-CoV-2 Omicron variant. The high transmission rates of SARS-CoV-2 favor the appearance of variants of the virus bearing a high number of changes in the genetic material, such as the Omicron variant. These changes might impact the efficacy of COVID-19 vaccines. Here, we evaluated the ability, of a highly adopted vaccination scheme in Brazil, of producing neutralizing antibodies, proteins present in the human body that bind to the virus and prevent infection, against the Omicron variant. This scheme consisted in two doses of the CoronaVac vaccine followed by an additional dose of the BNT162b2 vaccine. Our analysis showed that, before the additional dose, the number of individuals presenting neutralizing antibodies against Omicron was low and decreased over time. However, the production of neutralizing antibodies increased significantly after the BNT162b2 dose. Our findings support that this vaccination scheme improves the neutralization of Omicron. Campos et al. assessed the impact of a booster dose of BNT162b2 on antibody neutralization against the SARS-CoV-2 Omicron variant, following two doses of the CoronaVac vaccine. Neutralization mean titers against Omicron decrease over time following two doses of CoronaVac but increase again after the BNT162b2 booster, as does seroconversion.
Collapse
Affiliation(s)
- Guilherme R F Campos
- Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil
| | | | - Priscilla Soares Filgueiras
- Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
| | - Camila Amormino Corsini
- Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
| | - Sarah Vieira Contin Gomes
- Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
| | - Daniel Alvim Pena de Miranda
- Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
| | - Jéssica Vieira de Assis
- Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
| | - Thaís Bárbara de Souza Silva
- Laboratório de Imunologia de Doenças Virais, Instituto Rene Rachou-Fundação Oswaldo Cruz, Belo Horizonte, Brazil
| | - Pedro Augusto Alves
- Laboratório de Imunologia de Doenças Virais, Instituto Rene Rachou-Fundação Oswaldo Cruz, Belo Horizonte, Brazil
| | - Gabriel da Rocha Fernandes
- Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil
| | | | - Paula Rahal
- Laboratório de Estudos Genômicos, Departamento de Biologia, Instituto de Biociências Letras e Ciências Exatas (IBILCE), Universidade Estadual Paulista (Unesp), São José do Rio Preto, Brazil
| | - Rafaella Fortini Queiroz Grenfell
- Diagnosis and Therapy of Infectious Diseases and Cancer, Oswaldo Cruz Foundation (Fiocruz), Belo Horizonte, Brazil.,Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA USA
| | - Maurício L Nogueira
- Laboratório de Pesquisas em Virologia (LPV), Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil.,Hospital de Base, São José do Rio Preto, Brazil.,Department of Pathology, University of Texas Medical Branch, Galveston, TX USA
| |
Collapse
|